<span item_type="fundamental" item_id="94be8079666d5cd2f52e6ba4ebd85c87" counter_id="ST/US/USPH" env="prod"></span><span item_type="announcement" item_id="546776361153271553" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 197.34 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.58, missing the estimate of USD 0.67.</p><p>EBIT: As of FY2025 Q2, the actual value is USD 24.94 M.</p><p></p><h3>Adjusted EBITDA</h3><ul><li>Adjusted EBITDA was $26.9 million for the three months ended June 30, 2025, an increase of $4.7 million, or 21.4%, from $22.1 million for the three months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Net Income</h3><ul><li>Net income attributable to USPH’s shareholders was $12.4 million for the 2025 Second Quarter compared to $7.5 million for the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Operating Results</h3><ul><li>Operating Results was $12.4 million for the 2025 Second Quarter compared to $11.0 million for the 2024 Second Quarter, an increase of 11.8%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Revenue</h3><ul><li>Total revenue from physical therapy operations for the 2025 Second Quarter increased $24.8 million, or 17.3%, to $168.3 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Industrial injury prevention services revenue was $29.1 million for the 2025 Second Quarter, an increase of 22.6% compared to the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Gross Profit</h3><ul><li>Gross profit from physical therapy operations for the 2025 Second Quarter was $35.2 million with a gross profit margin of 20.9% compared to $28.8 million with a gross profit margin of 20.1% for the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Gross profit from IIP operations for the 2025 Second Quarter increased $1.3 million, or 25.8%, to $6.4 million from $5.1 million for the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Operating Costs</h3><ul><li>Operating costs from physical therapy operations increased $18.4 million, or 16.0%, to $133.1 million for the 2025 Second Quarter from $114.7 million for the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Salaries and related costs per visit was $60.08 for the 2025 Second Quarter compared to $59.66 for the 2024 Second Quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Total operating costs per visit was $83.95 compared to $84.46 in the prior year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash provided by operating activities was $30.2 million for the six months ended June 30, 2025, compared to $33.4 million for the six months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Net cash used in investing activities was - $19.3 million for the six months ended June 30, 2025, compared to - $48.8 million for the six months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>Net cash used in financing activities was - $18.1 million for the six months ended June 30, 2025, compared to - $24.6 million for the six months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Management increased its guidance for Adjusted EBITDA for full-year 2025 to a range of $93.0 million to $97.0 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li><li>The annual earnings guidance figures will not be updated unless there is a material development that causes management to believe that Adjusted EBITDA will be significantly outside the given range.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/885978/000088597825000041/ex99-1.htm"></span></li></ul>

U.S. Physical Therapy | 8-K: FY2025 Q2 Revenue: USD 197.34 M